Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients

Novartis47 enrolled

Overview

The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Liver Transplant

Interventions

Cyclosporine microemulsionDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least 4 months post-transplant * Patients in treatment with tacrolimus * Post-transplant diabetes treated with insulin for at least one month Exclusion Criteria * Known hypersensitivity to cyclosporine microemulsion * Investigational drug within 60 days before baseline or during the study * Patients who cannot comply with the study requirements Other protocol-defined exclusion criteria applied

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.